Qun Tang | Drug Discovery and Development | Best Researcher Award
Dr. Qun Tang, Nanchang university, China
Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents đ§˛, arsenic-derived anticancer drugs đ, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches đ§Ź. With 46 SCI papers, 1,489 citations đ, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.
Publication ProfileÂ
Education
Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) đ. After postdoctoral collaborations in South Korea and Sweden đ, he returned to Nanchang University in March 2010 to begin his independent research career đŹ. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 𧲠and the development of novel arsenic-based anticancer drugs đ. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions đ§Ź. His contributions continue to shape pharmaceutical innovation globally.
Professional Memberships
Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society đď¸. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level đ. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond đ¤. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research đđŹ. This role further enhances his influence within China’s scientific and medical communities.
Research Focus
Dr.âŻQunâŻTangâs research squarely targets phosphateâmodulated liver oncology and theranostics đ§ŹđŠş. He engineers inorganicâphosphate binders and polymeric drugâloading beads đ¤ to perform transâarterial embolization, simultaneously starving tumors and reshaping the microâenvironment đŻ. By blocking XPR1âmediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells âĄď¸, while lowâPi stress irreversibly repolarizes tumorâassociated macrophages đĄď¸ and dampens angiogenesis đą. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis đ§Ť. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge nextâgen therapies for liver cancer and chronic liver disease.
Publication Top Notes
- Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer
- Design and progress of drug-loading polymeric bead for tumor embolization
- Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?
- Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells
- Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma